Ignite Creation Date:
2025-12-24 @ 6:28 PM
Ignite Modification Date:
2025-12-29 @ 10:46 AM
Study NCT ID:
NCT05928468
Status:
UNKNOWN
Last Update Posted:
2023-07-03
First Post:
2023-06-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Safety and Immunogenicity Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB002
Sponsor:
Guangzhou Patronus Biotech Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-04-25
Start Date Type:
ACTUAL
Primary Completion Date:
2023-07-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-11-30
Completion Date Type:
ESTIMATED
First Submit Date:
2023-06-29
First Submit QC Date:
None
Study First Post Date:
2023-07-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-06-29
Last Update Post Date:
2023-07-03
Last Update Post Date Type:
ACTUAL